S. Vincent Rajkumar, MD

S. Vincent Rajkumar, MD, professor of medicine, Mayo Clinic, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.

The findings of the phase III trial, labeled SWOG S0777, showed a 13-month improvement in progression-free survival and a 29% reduction of risk of death with the triplet of bortezomib, lenalidomide, and dexamethasone, compared with lenalidomide and dexamethasone alone. Findings from the study suggest the triplet should be a new standard of care for untreated patients with multiple myeloma. Rajkumar said the triplet is now the new standard of care at the Mayo Clinic for multiple myeloma.

Videos

S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.

S. Vincent Rajkumar, MD | Authors

Articles

Dr. S. Vincent Rajkumar on a New Bortezomib Triplet in Multiple Myeloma